Literature DB >> 19459990

How reliable is an undetectable viral load?

Christophe Combescure1, N Vallier, B Ledergerber, M Cavassini, H Furrer, A Rauch, M Battegay, E Bernasconi, P Vernazza, B Hirschel.   

Abstract

OBJECTIVES: An article by the Swiss AIDS Commission states that patients with stably suppressed viraemia [i.e. several successive HIV-1 RNA plasma concentrations (viral loads, VL) below the limits of detection during 6 months or more of highly active antiretroviral therapy (HAART)] are unlikely to be infectious. Questions then arise: how reliable is the undetectability of the VL, given the history of measures? What factors determine reliability?
METHODS: We assessed the probability (henceforth termed reliability) that the n+1 VL would exceed 50 or 1000 HIV-1 RNA copies/mL when the nth one had been <50 copies/mL in 6168 patients of the Swiss HIV Cohort Study who were continuing to take HAART between 2003 and 2007. General estimating equations were used to analyse potential factors of reliability.
RESULTS: With a cut-off at 50 copies/mL, reliability was 84.5% (n=1), increasing to 94.5% (n=5). Compliance, the current type of HAART and the first antiretroviral therapy (ART) received (HAART or not) were predictive factors of reliability. With a cut-off at 1000 copies/mL, reliability was 97.5% (n=1), increasing to 99.1% (n=4). Chart review revealed that patients had stopped their treatment, admitted to major problems with compliance or were taking non-HAART ART in 72.2% of these cases. Viral escape caused by resistance was found in 5.6%. No explanation was found in the charts of 22.2% of cases.
CONCLUSIONS: After several successive VLs at <50 copies/mL, reliability reaches approximately 94% with a cut-off of 50 copies/mL and approximately 99% with a cut-off at 1000 copies/mL. Compliance is the most important factor predicting reliability.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19459990     DOI: 10.1111/j.1468-1293.2009.00714.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  4 in total

1.  Sexually transmitted infections and infectiousness beliefs among people living with HIV/AIDS: implications for HIV treatment as prevention.

Authors:  S C Kalichman; L Eaton; C Cherry
Journal:  HIV Med       Date:  2010-03-01       Impact factor: 3.180

Review 2.  Microbicides in the prevention of HIV infection: current status and future directions.

Authors:  Jeremy Nuttall
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

3.  A fission yeast cell-based system for multidrug resistant HIV-1 proteases.

Authors:  Zsigmond Benko; Dong Liang; Ge Li; Robert T Elder; Anindya Sarkar; Jun Takayama; Arun K Ghosh; Richard Y Zhao
Journal:  Cell Biosci       Date:  2017-01-11       Impact factor: 7.133

4.  Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (Schizosaccharomyces pombe).

Authors:  Jiantao Zhang; Kasey Vernon; Qi Li; Zsigmond Benko; Anthony Amoroso; Mohamed Nasr; Richard Y Zhao
Journal:  Pathogens       Date:  2021-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.